NCT00762112View on ClinicalTrials.gov

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Diabetes Mellitus
Interventions
DRUG

TAK-559

TAK-559 32 mg, tablets, orally, once daily for up to 24 months.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00762112 - Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter